Praxis Precision Medicines (PRAX)
(Real Time Quote from BATS)
$47.84 USD
-3.25 (-6.36%)
Updated Aug 5, 2025 03:36 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/05/2025
Time: -- |
9/2025 | $-3.40 | -13.59% |
Earnings Summary
For their last quarter, Praxis Precision Medicines (PRAX) reported earnings of -$3.31 per share, beating the Zacks Consensus Estimate of $-3.40 per share. This reflects a positive earnings surprise of 2.65%. Look out for PRAX's next earnings release expected on November 05, 2025. For the next earning release, we expect the company to report earnings of -$3.40 per share, reflecting a year-over-year decrease of 23.64%.
Earnings History
Price & Consensus
Zacks News for PRAX
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
PRAX FAQs
Based on past history, Zacks believes Praxis Precision Medicines, Inc. (PRAX) will report their next quarter earnings on November 05, 2025. For the next earning release, we expect the company to report earnings of -3.40 per share, reflecting a year-over-year increase of -23.64.
Based on past history, Zacks believes Praxis Precision Medicines, Inc. (PRAX) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 05, 2025.
The Zacks Consensus Estimate for Praxis Precision Medicines, Inc. (PRAX) for the quarter ending in September 2025 is $-3.40 a share. We expect Praxis Precision Medicines, Inc. to miss by -13.59%.
In the earnings report for the quarter ending in June 2024, Praxis Precision Medicines, Inc. (PRAX) announced earnings of $-1.74 per share versus the Zacks Consensus Estimate of $-2.38 per share, representing a surprise of -26.89%.